Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.95 CAD | +3.11% | +5.29% | +61.55% |
03-15 | Transcript : Cipher Pharmaceuticals Inc., Q4 2023 Earnings Call, Mar 15, 2024 | |
03-14 | Tranche Update on Cipher Pharmaceuticals Inc.'s Equity Buyback Plan announced on November 15, 2023. | CI |
Business Summary
Number of employees: 5
Sales per Business
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Specialty Pharmaceuticals
100.0
%
| 27 | 100.0 % | 29 | 100.0 % | +6.12% |
Sales per region
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Canada
60.0
%
| 16 | 60.0 % | 17 | 60.0 % | +6.12% |
United States
40.0
%
| 11 | 40.0 % | 11 | 40.0 % | +6.12% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Craig Mull
CEO | Chief Executive Officer | - | 19-03-25 |
Bryan Jacobs
DFI | Director of Finance/CFO | - | 22-08-14 |
James Bowen
IRC | Investor Relations Contact | - | - |
Emilio Presti
SAM | Sales & Marketing | - | - |
Diane Gajewczyk
PRN | Corporate Officer/Principal | - | 18-06-04 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Harold Wolkin
BRD | Director/Board Member | 72 | 16-08-07 |
Douglas N. Deeth
BRD | Director/Board Member | 76 | 23-06-20 |
Craig Mull
CEO | Chief Executive Officer | - | 19-03-25 |
Hubert Walinski
BRD | Director/Board Member | - | 23-06-20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 24,107,316 | 13,376,443 ( 55.49 %) | 0 | 55.49 % |
Company contact information
Cipher Pharmaceuticals, Inc.
5750 Explorer Drive Suite 404
L4W 0A9, Mississauga
+905-602-5840
http://www.cipherpharma.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+61.55% | 158M | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B |
- Stock Market
- Equities
- CPH Stock
- Company Cipher Pharmaceuticals Inc.